Le Lézard
Classified in: Health, Science and technology
Subjects: Product/Service, Business Update

PlaqueTec recruits first ten patients in BIOPATTERN trial

PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), today announced that it has received the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD. The trial has been designed to improve understanding of the pathobiology of atherosclerotic cardiovascular diseases (ACVD) and how it varies between individuals, to aid the development of novel therapies and treatment approaches.

The BIOPATTERN trial will use PlaqueTec's proprietary blood sampling device, the Liquid Biopsy Systemtm (LBS), to collect samples at multiple sites along a patient's diseased coronary artery. Thousands of proteins and other blood molecules will be measured in each sample, enabling the assessment of trans-plaque gradients between samples. These data will be analysed and used to generate a more detailed picture of the disease and enhance clinicians' understanding of which proteins and biomolecules play key roles in CAD progression towards heart attack.

The trial aims to recruit 300 patients with established CAD who have been scheduled for a coronary angiogram. Patients will be recruited across eight UK NHS specialist cardiac centres, with four sites now open, including lead site Royal Papworth Hospital in Cambridge, UK, where Chief Investigator Dr Stephen Hoole is an interventional cardiologist, and Norfolk and Norwich University Hospital, Royal Bournemouth Hospital, and the Bristol Heart Institute. The trial is managed by Papworth Trials Unit Collaboration in collaboration with PlaqueTec and is overseen by a Trial Steering Committee chaired by Professor Peter Libby (Mallinckrodt Professor of Medicine, Harvard Medical School and President of the International Atherosclerosis Society).

CVD is the leading cause of death worldwide, with CAD being the most common type, accounting for 49% of the 18.6 million CVD-related deaths in 2019.1 The BIOPATTERN trial will establish the safety and functionality of the LBS device and confirm trans-plaque protein signals seen in earlier pilot studies. PlaqueTec then aims to use the data collected to generate a new data platform based on novel site-of-disease insights to enable the stratification of patients with distinct disease endotypes and the development of precision medicine approaches to improve treatment outcomes for patients with CAD.

"A population approach to managing cardiovascular risk is generally used at present to treat CAD patients and prevent progression to heart attack, whereas a more tailored, precision medicine approach that accounts for each patient's individual disease profile and health needs has exciting potential benefits. By better targeting of new therapies to those patients at highest risk and who most need them, we hope to efficiently stabilise their disease and improve outcomes." said Dr Stephen Hoole, Consultant Cardiologist, Royal Papworth Hospital. "The BIOPATTERN trial provides a novel opportunity to use the LBS device to help us better understand and characterise CAD on an individual patient level and potentially enable better patient care by identifying novel precision medicine targeted treatments to improve the outcome of patients with CAD in the future."

Dr Simon Williams, General Manager, PlaqueTec, commented: "Reaching the 10-patient landmark and securing MHRA approval to continue to recruit to the BIOPATTERN trial is a huge success and enables us to pursue our ambition of opening a new frontier of precision medicine for patients with CAD. We are very grateful to all the patients and NHS site staff who have made this landmark possible and now look forward to progressing towards the 300-patient target."

The PlaqueTec LBS has been successfully validated in first-in-human and proof-of-concept trials.2 To learn more about the BIOPATTERN trial, please visit https://www.plaquetec.com/our-research.

  1. World Heart Federation (2023) ?World Heart Report 2023'. Available at: World-Heart-Report-2023.pdf (world-heart-federation.org)
  2. West, N.E.J. et al. (2017) ?Percutaneous sampling of local biomolecule gradients across coronary artery atherosclerotic plaques', JACC: Basic to Translational Science, 2(6), pp. 646?654. doi:10.1016/j.jacbts.2017.07.007


These press releases may also interest you

at 02:44
International medical imaging IT and cybersecurity company Sectra (STO: SECT B) will provide its enterprise imaging solution to yet another healthcare provider in the US Midwest. The healthcare provider will utilize the radiology module to unify the...

at 02:05
The European Medicines Agency (EMA) has validated two marketing authorization applications (MAAs) for Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN) datopotamab deruxtecan (Dato-DXd) in two types of cancer. One MAA is for the...

at 02:00
RLDatix, the leading global provider of connected healthcare operations software and services, has finalized the acquisition of Breitenbach Software Engineering GmbH ("Breitenbach"), a Germany-based integrated solutions provider specializing in...

at 01:35
Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, will announce its preliminary results for the year ended 31 December 2023 on Thursday, 14 March 2024....

at 01:00
MEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab injection) for all approved indicationsDedicated retina sales and field reimbursement team integrated into Sandoz, ensuring seamless experience for...

News published on and distributed by: